dupilumab
regeneron,sanofi
['sanofi', 'regeneron']
today, we re presenting late-breaking results at #eadv2022 from our second pivotal trial in adults with #prurigonodularis. read the news: 
We chase the miracles of science to improve people’s lives.
Interactions with this account must comply with the Terms: https://t.co/mXmuqtkblm